ALK and non-small cell lung carcinoma: This retrospective observational study aimed to evaluate the clinical efficacy of ICI plus platinum combination chemotherapy in patients with NSCLC harboring rare oncogenic driver mutations other than EGFR mutation and ALK fusion.